Vasomotor Symptoms Market Analysis

Global Vasomotor Symptoms Market Overview

Vasomotor Symptoms Market Size was valued at USD 3.76 billion in 2023. The vasomotor symptoms market industry is projected to grow from USD 4.02 Billion in 2024 to USD 6.94 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.77% during the forecast period (2024 - 2032). Rising investing in R&D and clinical trial and increasing product development and innovations are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Vasomotor Symptoms Market Trends

• Growing research and development and clinical trial to boost market growth

The R&D and clinical trials provide a better understanding of the underlying mechanisms of vasomotor symptoms, including the hormonal changes and physiological processes involved. This increased understanding can lead to more targeted and effective treatment options, which can ultimately drive market CAGR. Clinical trials can help to develop new treatments for vasomotor symptoms, which can expand the options available to patients and drive market growth. For example, recent research has focused on non-hormonal treatments for vasomotor symptoms, such as selective serotonin reuptake inhibitors (SSRIs) and gabapentinoids, which could provide an alternative to hormone therapy. It can also provide evidence to support the efficacy and safety of existing treatments for vasomotor symptoms, which can increase their adoption and drive market growth. For instance, recent clinical trials have provided evidence to support the use of hormone therapy for vasomotor symptoms, which can reassure patients and healthcare providers about its safety and efficacy. However, R&D and clinical trials can also raise awareness about vasomotor symptoms and its impact on women's health, which can increase demand for treatments and drive market growth. Increased awareness can also lead to better diagnosis and treatment of vasomotor symptoms, which can improve patient outcomes and quality of life. For instance, Pfizer has been conducting clinical trials on a non-hormonal drug called lasofoxifene, which is being evaluated for the treatment of VMS.

The launch of new products or the development of new treatments can help to raise awareness about VMS and the importance of seeking treatment. This increased awareness can lead to more women seeking treatment for their symptoms, which can create a larger market for VMS treatments. The companies that are able to launch new products or develop new treatments for VMS can gain a competitive advantage in the market. This can lead to increased  vasomotor symptoms market revenue, particularly if the product is able to establish itself as a preferred treatment option among healthcare providers and patients. Furthermore, the launch of new products or the development of new treatments can also provide companies with patent protection, which can limit competition and create a more lucrative market for the product. However, there is currently a significant unmet need for safe and effective treatments for VMS. Women experiencing VMS often have limited options for treatment, and many available treatments have significant side effects or contraindications. The launch of new products or the development of new treatments can help to meet this unmet need and provide women with more effective and tolerable options for managing their symptoms. For instance, in 2019, TherapeuticsMD received FDA approval for Bijuva, a combination of estradiol and progesterone, for the treatment of moderate to severe VMS in postmenopausal women with a uterus.

Vasomotor Symptoms Market Segment Insights

Vasomotor Symptoms Therapy Type Insights

The vasomotor symptoms market segmentation, based on therapy type, includes hormonal, non-hormonal. The hormonal segment held the majority share in 2022 contribution to around ~65-67% in respect to the vasomotor symptoms market revenue. Hormonal therapy is a common treatment option for Vasomotor Symptoms (VMS), particularly for women who are experiencing menopause-related symptoms. Hormonal therapy involves the use of estrogen and/or progesterone to help alleviate VMS symptoms such as hot flashes, night sweats, and vaginal dryness.

In 2019: TherapeuticsMD launched a new hormonal therapy product called Bijuva, which is a combination of estradiol and progesterone. Bijuva is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

In 2020: Pfizer announced the launch of its new hormonal therapy product called Rilectomy. Rilectomy is a combination of estradiol and norethindrone acetate and is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Vasomotor Symptoms Distribution Channel Insights

The vasomotor symptoms market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies, online stores. The hospital pharmacies segment dominated the market in 2022. This is due to the increasing preference for metal implants due to the hospital pharmacy's accessibility to common medications and the need for prescriptions in order to buy such medications. With a CAGR of 8.3% during the projected period, the online stores segment is anticipated to develop the fastest. It is because online pharmacies have recently become popular. Furthermore, these platforms offer a ready discount. For instance, a programme offered by Tata 1 MG gives customers a flat discount of up to 20% when they buy allopathic medications. Users also receive an additional 5% off if they submit a doctor's prescription. The internet stores will expand as a result of the following models.

Figure 1 Vasomotor Symptoms Market, by Distribution Channel, 2022 & 2030 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Vasomotor Symptoms Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Vasomotor Symptoms market accounted for USD 1.6 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to due to the easily accessible knowledge about the existence of medications aiding in the relief of the symptoms of such a cause; in addition, up to 75% of females in the USA experience hot flashes around the time of menopause. In addition, the age at which the subsequent symptoms first appear is roughly 52 years old. Pharmaceutical giants like Pfizer and others have a grip in the area and frequently run campaigns about the availability and usage of such products.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 VASOMOTOR SYMPTOMS MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe vasomotor symptoms market accounts for the second-largest market share. This is indicated by the rise in different clinical trial research in European nations. For instance, Mithra Pharmaceuticals modified its clinical E4 Comfort program in 2020 with the goal of enrolling 2200 menopausal women. Further, the Germany vasomotor symptoms market held the largest market share, and the UK vasomotor symptoms market was the fastest growing market in the European region

The Asia-Pacific Vasomotor Symptoms Market is expected to grow at the fastest CAGR from 2022 to 2030. This is because women are becoming more educated and since there have been several campaigns to raise awareness of these symptoms and their widely accessible solutions. Moreover, menopause is no longer vilified as a disease as it has become accepted as a natural ageing phenomenon. The following has aided in the quick uptake of pharmaceuticals and medications and will continue to do so. Also, women in countries like India reach menopause much earlier than women in the west. According to observations, the average age for the same is 46.2 years, which is lower than the 51-year  average. Moreover, China vasomotor symptoms market held the largest market share, and the India vasomotor symptoms market was the fastest growing market in the Asia-Pacific region 

Vasomotor Symptoms Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the vasomotor symptoms market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the vasomotor symptoms industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the vasomotor symptoms industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, vasomotor symptoms industry has provided medicine with some of the most significant benefits. The vasomotor symptoms market major player such as Pfizer Inc. (US), TherapeuticsMD Inc. (US), Allergan (Ireland) and others are working to expand the market demand by investing in research and development activities.

Pfizer Inc. is a New York, US-based pharmaceutical manufacturing company and it was incorporated in 1848. Pfizer Inc. specialises in   medicines and equipment for a wide range of procedures such as immunology, oncology, cardiology, endocrinology, and neurology among others. The company has a workforce of 10,000 plus employees at 50 plus operating locations across the Asia, Europe, Oceania, Africa, and America regions. in 2020, Pfizer also received FDA approval for a new non-hormonal medication called Vylessi in 2019. Vylessi is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

TherapeuticsMD is a pharmaceutical company that specializes in the development and commercialization of women's health products. The company was founded in 2008 and is headquartered in Boca Raton, Florida. TherapeuticsMD's portfolio of products includes a range of hormone therapy and non-hormonal products for the treatment of various women's health conditions. In 2019, TherapeuticsMD also received FDA approval for another hormonal therapy product called Imvexxy in 2018. Imvexxy is a vaginal insert indicated for the treatment of moderate to severe dyspareunia (painful intercourse) associated with menopause.

Key Companies in the vasomotor symptoms market includes

• Allergan (Ireland)


• Pfizer Inc. (US)


• Eli Lily and Company (US)


• Novartis AG (Switzerland)


• Emcure Pharmaceuticals Ltd (India)


• Merck & Co.Inc. (US)


• TherapeuticsMD Inc. (US)


• Mithra Pharmaceuticals (Belgium), among others

Vasomotor Symptoms Industry Developments

In 2020: Novo Nordisk announced that it had received FDA approval for a new non-hormonal medication called Rybelsus. While Rybelsus is indicated for the treatment of type 2 diabetes, it has also been shown to reduce the frequency and severity of hot flashes in women.

In 2021: Evgen Pharma announced that it had received FDA approval to initiate a Phase II clinical trial of its non-hormonal medication, SFX-01, for the treatment of hot flashes and night sweats in women with breast cancer.

Vasomotor Symptoms Market Segmentation

Vasomotor Symptoms Therapy Type Outlook

• Hormonal


• Non-Hormonal

Vasomotor Symptoms Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Stores

Vasomotor Symptoms Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America